Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 Program

NEXT STORY
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
PREV STORY
Global Capillary Blood Collection Devices Market, 2017-2018 & 2025: Increasing Incidence of Chronic, Infectious and Autoimmune Diseases Propelling Market Growth
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting

HAMPTON, N.J., May 17, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today ...

author_avatar
NASDAQ Market News

Santhera’s Raxone® Receives First Positive EAMS Scientific Opinion from UK’s MHRA in Duchenne Muscular Dystrophy

Liestal, Switzerland, June 22, 2017 - Santhera Pharmaceuticals (SIX: SANN) announces that the UK's Medicines and ...

author_avatar
NASDAQ Market News

A 19ª Conferência Mundial sobre Câncer de Pulmão da IASLC chega a Toronto, Canadá

DENVER, Aug. 22, 2018 (GLOBE NEWSWIRE) -- O quê: A Associação Internacional para Estudo do ...

author_avatar
NASDAQ Market News